APO Research
Talk to an analyst

APO RESEARCH · REPORT

Lyme Disease Testing

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Lyme Disease Testing Market Outlook and Growth Opportunities 2026

6 January 2026192 pages

Choose your research edition.

Industry ResearchLyme Disease Testing Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Lyme Disease Testing Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Lyme Disease Testing Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Lyme Disease Testing Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Lyme Disease Testing Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Lyme Disease Testing market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Lyme Disease Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Lyme Disease Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Lyme Disease Testing is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Lyme Disease Testing market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Lyme Disease Testing market include Quidel Corporation, Roche Holding AG, Fujirebio(H.U. Group Holdings), ZEUS Scientific, IGeneX, Thermo Fisher Scientific, Everlywell, Oxford Immunotec Global PLC(PerkinElmer) and BioMerieux, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Lyme Disease Testing market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Lyme Disease Testing and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Lyme Disease Testing revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Lyme Disease Testing market.

Lyme Disease Testing Segment by Company

Quidel Corporation

Roche Holding AG

Fujirebio(H.U. Group Holdings)

ZEUS Scientific

IGeneX

Thermo Fisher Scientific

Everlywell

Oxford Immunotec Global PLC(PerkinElmer)

BioMerieux

Bio-Rad Laboratories

T2 Biosystems

Lyme Disease Testing Segment by Type

ELISA

Western Blotting

PCR

Others

Lyme Disease Testing Segment by Application

Hospital and Testing Agency

Personal

Lyme Disease Testing Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Lyme Disease Testing status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Lyme Disease Testing key companies, revenue, market share, and recent developments.

3. To split the Lyme Disease Testing breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Lyme Disease Testing market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Lyme Disease Testing significant trends, drivers, influence factors in global and regions.

6. To analyze Lyme Disease Testing competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lyme Disease Testing market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Lyme Disease Testing and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lyme Disease Testing.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Lyme Disease Testing industry.

Chapter 3: Detailed analysis of Lyme Disease Testing company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Lyme Disease Testing in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Lyme Disease Testing in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Lyme Disease Testing Industry Trends Table 2. Lyme Disease Testing Industry Drivers Table 3. Lyme Disease Testing Industry Opportunities and Challenges Table 4. Lyme Disease Testing Industry Restraints Table 5. Global Lyme Disease Testing Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Lyme Disease Testing Revenue Share by Company (2021-2026) Table 7. Global Lyme Disease Testing Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Lyme Disease Testing Key Company Manufacturing Base & Headquarters Table 9. Global Lyme Disease Testing Company, Product Type & Application Table 10. Global Lyme Disease Testing Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Lyme Disease Testing by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of ELISA Table 15. Significant Companies of Western Blotting Table 16. Significant Companies of PCR Table 17. Significant Companies of Others Table 18. Global Lyme Disease Testing Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Lyme Disease Testing Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Lyme Disease Testing Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Lyme Disease Testing Sales Value Share by Type (2021-2026) Table 22. Global Lyme Disease Testing Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Hospital and Testing Agency Table 24. Significant Companies of Personal Table 25. Global Lyme Disease Testing Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Lyme Disease Testing Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Lyme Disease Testing Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Lyme Disease Testing Sales Value Share by Application (2021-2026) Table 29. Global Lyme Disease Testing Sales Value Share by Application (2027-2032) Table 30. Global Lyme Disease Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Lyme Disease Testing Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Lyme Disease Testing Sales Value Share by Region (2021-2026) Table 33. Global Lyme Disease Testing Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Lyme Disease Testing Sales Value Share by Region (2027-2032) Table 35. Global Lyme Disease Testing Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Lyme Disease Testing Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Lyme Disease Testing Sales Value Market Share by Country (2021-2026) Table 38. Global Lyme Disease Testing Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Lyme Disease Testing Sales Value Market Share by Country (2027-2032) Table 40. Quidel Corporation Company Information Table 41. Quidel Corporation Business Overview Table 42. Quidel Corporation Lyme Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Quidel Corporation Lyme Disease Testing Product Portfolio Table 44. Quidel Corporation Recent Development Table 45. Roche Holding AG Company Information Table 46. Roche Holding AG Business Overview Table 47. Roche Holding AG Lyme Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Roche Holding AG Lyme Disease Testing Product Portfolio Table 49. Roche Holding AG Recent Development Table 50. Fujirebio(H.U. Group Holdings) Company Information Table 51. Fujirebio(H.U. Group Holdings) Business Overview Table 52. Fujirebio(H.U. Group Holdings) Lyme Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Fujirebio(H.U. Group Holdings) Lyme Disease Testing Product Portfolio Table 54. Fujirebio(H.U. Group Holdings) Recent Development Table 55. ZEUS Scientific Company Information Table 56. ZEUS Scientific Business Overview Table 57. ZEUS Scientific Lyme Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. ZEUS Scientific Lyme Disease Testing Product Portfolio Table 59. ZEUS Scientific Recent Development Table 60. IGeneX Company Information Table 61. IGeneX Business Overview Table 62. IGeneX Lyme Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. IGeneX Lyme Disease Testing Product Portfolio Table 64. IGeneX Recent Development Table 65. Thermo Fisher Scientific Company Information Table 66. Thermo Fisher Scientific Business Overview Table 67. Thermo Fisher Scientific Lyme Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Thermo Fisher Scientific Lyme Disease Testing Product Portfolio Table 69. Thermo Fisher Scientific Recent Development Table 70. Everlywell Company Information Table 71. Everlywell Business Overview Table 72. Everlywell Lyme Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Everlywell Lyme Disease Testing Product Portfolio Table 74. Everlywell Recent Development Table 75. Oxford Immunotec Global PLC(PerkinElmer) Company Information Table 76. Oxford Immunotec Global PLC(PerkinElmer) Business Overview Table 77. Oxford Immunotec Global PLC(PerkinElmer) Lyme Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Oxford Immunotec Global PLC(PerkinElmer) Lyme Disease Testing Product Portfolio Table 79. Oxford Immunotec Global PLC(PerkinElmer) Recent Development Table 80. BioMerieux Company Information Table 81. BioMerieux Business Overview Table 82. BioMerieux Lyme Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. BioMerieux Lyme Disease Testing Product Portfolio Table 84. BioMerieux Recent Development Table 85. Bio-Rad Laboratories Company Information Table 86. Bio-Rad Laboratories Business Overview Table 87. Bio-Rad Laboratories Lyme Disease Testing Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Bio-Rad Laboratories Lyme Disease Testing Product Portfolio Table 89. Bio-Rad Laboratories Recent Development Table 90. T2 Biosystems Company Information Table 91. T2 Biosystems Business Overview Table 92. T2 Biosystems Lyme Disease Testing Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. T2 Biosystems Lyme Disease Testing Product Portfolio Table 94. T2 Biosystems Recent Development Table 95. Research Programs/Design for This Report Table 96. Authors List of This Report Table 97. Secondary Sources Table 98. Primary Sources List of Figures Figure 1. Lyme Disease Testing Product Image Figure 2. Global Lyme Disease Testing Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Lyme Disease Testing Market Size (2021-2032) & (US$ Million) Figure 4. Global Lyme Disease Testing Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. ELISA Image Figure 8. Western Blotting Image Figure 9. PCR Image Figure 10. Others Image Figure 11. Global Lyme Disease Testing Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Lyme Disease Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Lyme Disease Testing Sales Value Share by Type (2021-2032) Figure 14. Hospital and Testing Agency Image Figure 15. Personal Image Figure 16. Global Lyme Disease Testing Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Lyme Disease Testing Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Lyme Disease Testing Sales Value Share by Application (2021-2032) Figure 19. Global Lyme Disease Testing Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Lyme Disease Testing Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Lyme Disease Testing Sales Value (2021-2032) & (US$ Million) Figure 22. North America Lyme Disease Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Lyme Disease Testing Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Lyme Disease Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Lyme Disease Testing Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Lyme Disease Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Lyme Disease Testing Sales Value (2021-2032) & (US$ Million) Figure 28. South America Lyme Disease Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Lyme Disease Testing Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Lyme Disease Testing Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Lyme Disease Testing Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • ELISA
  • Western Blotting
  • PCR
  • Others
Applications
  • Hospital and Testing Agency
  • Personal
Companies covered
  • Quidel Corporation
  • Roche Holding AG
  • Fujirebio(H.U. Group Holdings)
  • ZEUS Scientific
  • IGeneX
  • Thermo Fisher Scientific
  • Everlywell
  • Oxford Immunotec Global PLC(PerkinElmer)
  • BioMerieux
  • Bio-Rad Laboratories
  • T2 Biosystems

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Lyme Disease Testing Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Lyme Disease Testing Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Lyme Disease Testing Market Dynamics
  1. 2.1 Lyme Disease Testing Industry Trends
  2. 2.2 Lyme Disease Testing Industry Drivers
  3. 2.3 Lyme Disease Testing Industry Opportunities and Challenges
  4. 2.4 Lyme Disease Testing Industry Restraints
3 Lyme Disease Testing Market by Company
  1. 3.1 Global Lyme Disease Testing Company Revenue Ranking in 2025
  2. 3.2 Global Lyme Disease Testing Revenue by Company (2021-2026)
  3. 3.3 Global Lyme Disease Testing Company Ranking (2024-2026)
  4. 3.4 Global Lyme Disease Testing Company Manufacturing Base and Headquarters
  5. 3.5 Global Lyme Disease Testing Company Product Type and Application
  6. 3.6 Global Lyme Disease Testing Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Lyme Disease Testing Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Lyme Disease Testing Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Lyme Disease Testing Market by Type
  1. 4.1 Lyme Disease Testing Type Introduction
  2. 4.1.1 ELISA
  3. 4.1.2 Western Blotting
  4. 4.1.3 PCR
  5. 4.1.4 Others
  6. 4.2 Global Lyme Disease Testing Sales Value by Type
  7. 4.2.1 Global Lyme Disease Testing Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Lyme Disease Testing Sales Value by Type (2021-2032)
  9. 4.2.3 Global Lyme Disease Testing Sales Value Share by Type (2021-2032)
5 Lyme Disease Testing Market by Application
  1. 5.1 Lyme Disease Testing Application Introduction
  2. 5.1.1 Hospital and Testing Agency
  3. 5.1.2 Personal
  4. 5.2 Global Lyme Disease Testing Sales Value by Application
  5. 5.2.1 Global Lyme Disease Testing Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Lyme Disease Testing Sales Value by Application (2021-2032)
  7. 5.2.3 Global Lyme Disease Testing Sales Value Share by Application (2021-2032)
6 Lyme Disease Testing Regional Value Analysis
  1. 6.1 Global Lyme Disease Testing Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Lyme Disease Testing Sales Value by Region (2021-2032)
  3. 6.2.1 Global Lyme Disease Testing Sales Value by Region: 2021-2026
  4. 6.2.2 Global Lyme Disease Testing Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Lyme Disease Testing Sales Value (2021-2032)
  7. 6.3.2 North America Lyme Disease Testing Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Lyme Disease Testing Sales Value (2021-2032)
  10. 6.4.2 Europe Lyme Disease Testing Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Lyme Disease Testing Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Lyme Disease Testing Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Lyme Disease Testing Sales Value (2021-2032)
  16. 6.6.2 South America Lyme Disease Testing Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Lyme Disease Testing Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Lyme Disease Testing Sales Value Share by Country, 2025 VS 2032
7 Lyme Disease Testing Country-level Value Analysis
  1. 7.1 Global Lyme Disease Testing Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Lyme Disease Testing Sales Value by Country (2021-2032)
  3. 7.2.1 Global Lyme Disease Testing Sales Value by Country (2021-2026)
  4. 7.2.2 Global Lyme Disease Testing Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Lyme Disease Testing Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Lyme Disease Testing Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Lyme Disease Testing Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Quidel Corporation
  2. 8.1.1 Quidel Corporation Company Information
  3. 8.1.2 Quidel Corporation Business Overview
  4. 8.1.3 Quidel Corporation Lyme Disease Testing Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Quidel Corporation Lyme Disease Testing Product Portfolio
  6. 8.1.5 Quidel Corporation Recent Developments
  7. 8.2 Roche Holding AG
  8. 8.2.1 Roche Holding AG Company Information
  9. 8.2.2 Roche Holding AG Business Overview
  10. 8.2.3 Roche Holding AG Lyme Disease Testing Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Roche Holding AG Lyme Disease Testing Product Portfolio
  12. 8.2.5 Roche Holding AG Recent Developments
  13. 8.3 Fujirebio(H.U. Group Holdings)
  14. 8.3.1 Fujirebio(H.U. Group Holdings) Company Information
  15. 8.3.2 Fujirebio(H.U. Group Holdings) Business Overview
  16. 8.3.3 Fujirebio(H.U. Group Holdings) Lyme Disease Testing Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Fujirebio(H.U. Group Holdings) Lyme Disease Testing Product Portfolio
  18. 8.3.5 Fujirebio(H.U. Group Holdings) Recent Developments
  19. 8.4 ZEUS Scientific
  20. 8.4.1 ZEUS Scientific Company Information
  21. 8.4.2 ZEUS Scientific Business Overview
  22. 8.4.3 ZEUS Scientific Lyme Disease Testing Revenue and Gross Margin (2021-2026)
  23. 8.4.4 ZEUS Scientific Lyme Disease Testing Product Portfolio
  24. 8.4.5 ZEUS Scientific Recent Developments
  25. 8.5 IGeneX
  26. 8.5.1 IGeneX Company Information
  27. 8.5.2 IGeneX Business Overview
  28. 8.5.3 IGeneX Lyme Disease Testing Revenue and Gross Margin (2021-2026)
  29. 8.5.4 IGeneX Lyme Disease Testing Product Portfolio
  30. 8.5.5 IGeneX Recent Developments
  31. 8.6 Thermo Fisher Scientific
  32. 8.6.1 Thermo Fisher Scientific Company Information
  33. 8.6.2 Thermo Fisher Scientific Business Overview
  34. 8.6.3 Thermo Fisher Scientific Lyme Disease Testing Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Thermo Fisher Scientific Lyme Disease Testing Product Portfolio
  36. 8.6.5 Thermo Fisher Scientific Recent Developments
  37. 8.7 Everlywell
  38. 8.7.1 Everlywell Company Information
  39. 8.7.2 Everlywell Business Overview
  40. 8.7.3 Everlywell Lyme Disease Testing Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Everlywell Lyme Disease Testing Product Portfolio
  42. 8.7.5 Everlywell Recent Developments
  43. 8.8 Oxford Immunotec Global PLC(PerkinElmer)
  44. 8.8.1 Oxford Immunotec Global PLC(PerkinElmer) Company Information
  45. 8.8.2 Oxford Immunotec Global PLC(PerkinElmer) Business Overview
  46. 8.8.3 Oxford Immunotec Global PLC(PerkinElmer) Lyme Disease Testing Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Oxford Immunotec Global PLC(PerkinElmer) Lyme Disease Testing Product Portfolio
  48. 8.8.5 Oxford Immunotec Global PLC(PerkinElmer) Recent Developments
  49. 8.9 BioMerieux
  50. 8.9.1 BioMerieux Company Information
  51. 8.9.2 BioMerieux Business Overview
  52. 8.9.3 BioMerieux Lyme Disease Testing Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BioMerieux Lyme Disease Testing Product Portfolio
  54. 8.9.5 BioMerieux Recent Developments
  55. 8.10 Bio-Rad Laboratories
  56. 8.10.1 Bio-Rad Laboratories Company Information
  57. 8.10.2 Bio-Rad Laboratories Business Overview
  58. 8.10.3 Bio-Rad Laboratories Lyme Disease Testing Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Bio-Rad Laboratories Lyme Disease Testing Product Portfolio
  60. 8.10.5 Bio-Rad Laboratories Recent Developments
  61. 8.11 T2 Biosystems
  62. 8.11.1 T2 Biosystems Company Information
  63. 8.11.2 T2 Biosystems Business Overview
  64. 8.11.3 T2 Biosystems Lyme Disease Testing Revenue and Gross Margin (2021-2026)
  65. 8.11.4 T2 Biosystems Lyme Disease Testing Product Portfolio
  66. 8.11.5 T2 Biosystems Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst